BR9608241A - Proteìna de membrana externa maior de moraxella com alto peso molecular - Google Patents
Proteìna de membrana externa maior de moraxella com alto peso molecularInfo
- Publication number
- BR9608241A BR9608241A BR9608241-0A BR9608241A BR9608241A BR 9608241 A BR9608241 A BR 9608241A BR 9608241 A BR9608241 A BR 9608241A BR 9608241 A BR9608241 A BR 9608241A
- Authority
- BR
- Brazil
- Prior art keywords
- outer membrane
- membrane protein
- moraxella
- molecular weight
- 200kda
- Prior art date
Links
- 101710116435 Outer membrane protein Proteins 0.000 title abstract 5
- 241000588621 Moraxella Species 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 241000588655 Moraxella catarrhalis Species 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/803—Antibody or antigen-binding fragment thereof that binds gram-negative bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<B>PROTEìNA DE MEMEBRANA EXTERNA MAIOR DE MORAXELLA COM ALTO PESO MOLECULAR<D> Proteína de membrana externa isolada e purificada de uma cepa de Moraxella, particularmente M. catarrhalis, tendo uma massa molecular de cerca de 250kDa é descrita. A proteína de membrana externa de cerca de 200kDa, bem como moléculas de ácido nucléico codificando a mesma, são úteis em aplicações de diagnóstico e composições imunogênicas, particularmente para administração in vivo a um hospedeiro para conferir proteção contra doença causada por um agente patogênico bacteriano que produz a proteína de membrana externa de cerca de 200kDa, ou produz uma proteína capaz de induzir anticorpos em um hospedeiro especificamente reativo a proteína de membrana externa de cerca de 200kDa.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/431,718 US6335018B1 (en) | 1995-05-01 | 1995-05-01 | High molecular weight major outer membrane protein of moraxella |
US08/478,370 US5808024A (en) | 1995-05-01 | 1995-06-07 | Nucleic acids encoding high molecular weight major outer membrane protein of moraxella |
US08/621,944 US6440425B1 (en) | 1995-05-01 | 1996-03-26 | High molecular weight major outer membrane protein of moraxella |
PCT/CA1996/000264 WO1996034960A1 (en) | 1995-05-01 | 1996-04-29 | High molecular weight major outer membrane protein of moraxella |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9608241A true BR9608241A (pt) | 2001-07-31 |
Family
ID=27411748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9608241-0A BR9608241A (pt) | 1995-05-01 | 1996-04-29 | Proteìna de membrana externa maior de moraxella com alto peso molecular |
Country Status (9)
Country | Link |
---|---|
US (4) | US6440425B1 (pt) |
EP (1) | EP0826052A1 (pt) |
JP (1) | JP3771265B2 (pt) |
AU (1) | AU722132B2 (pt) |
BR (1) | BR9608241A (pt) |
CA (1) | CA2219889A1 (pt) |
HK (1) | HK1015412A1 (pt) |
MX (1) | MX9708438A (pt) |
WO (1) | WO1996034960A1 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440425B1 (en) * | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US7341727B1 (en) * | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
CA2274495C (en) | 1996-12-20 | 2009-06-02 | Board Of Regents, The University Of Texas System | Uspa1 and uspa2 antigens of moraxella catarrhalis |
GB9808720D0 (en) * | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
AU4260099A (en) * | 1998-05-12 | 1999-11-29 | Smithkline Beecham Biologicals (Sa) | Compounds from moraxella catarrhalis |
GB9810285D0 (en) * | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
US6541616B1 (en) | 1998-10-01 | 2003-04-01 | Antex Biologics Inc. | Moraxella catarrhalis protein, gene sequence and uses thereof |
CZ303653B6 (cs) | 1999-03-19 | 2013-01-30 | Smithkline Beecham Biologicals S. A. | Imunogenní prostredek |
GB9915031D0 (en) * | 1999-06-25 | 1999-08-25 | Smithkline Beecham Biolog | Novel compounds |
US6391313B1 (en) * | 1999-07-15 | 2002-05-21 | Aventis Pasteur Limited | Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis |
NZ517235A (en) * | 1999-07-27 | 2004-01-30 | Aventis Pasteur | Recombinant high molecular weight major outer membrane protein of moraxella |
GB9917977D0 (en) * | 1999-07-30 | 1999-09-29 | Smithkline Beecham Biolog | Novel compounds |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
SE0102410D0 (sv) | 2001-07-04 | 2001-07-04 | Arne Forsgren | Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis |
KR101239242B1 (ko) | 2002-08-02 | 2013-03-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 항원 조합물을 포함하는 나이세리아 백신 조성물 |
JP4777873B2 (ja) * | 2003-02-14 | 2011-09-21 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 親油性薬物送達ビヒクルおよびこれらの使用方法 |
ES2537274T3 (es) * | 2005-08-10 | 2015-06-05 | Arne Forsgren Ab | Interacción de Moraxella catarrhalis con células epiteliales, proteínas de la matriz extracelular y el sistema del complemento |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
CA2808919C (en) | 2005-12-22 | 2016-04-19 | Glaxosmithkline Biologicals S.A. | Streptococcus pneumoniae capsular saccharide vaccine |
BRPI0707154B8 (pt) | 2006-01-17 | 2022-12-20 | Forsgren Arne | composição de vacina |
EP2687228B1 (en) | 2007-06-26 | 2017-07-19 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
US8268796B2 (en) | 2008-06-27 | 2012-09-18 | Children's Hospital & Research Center At Oakland | Lipophilic nucleic acid delivery vehicle and methods of use thereof |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
CN102869377A (zh) | 2010-03-10 | 2013-01-09 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
KR20220056884A (ko) | 2011-04-22 | 2022-05-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 변이체 캡시드를 지니는 아데노-관련 바이러스 및 이의 사용 방법 |
ES2897508T3 (es) | 2013-05-31 | 2022-03-01 | Univ California | Variantes de virus adenoasociados y métodos de uso de las mismas |
SG10201810150UA (en) | 2014-03-17 | 2018-12-28 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression in cone cells |
WO2016141078A1 (en) | 2015-03-02 | 2016-09-09 | Avalanche Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
WO2016154344A1 (en) | 2015-03-24 | 2016-09-29 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
CN116286986A (zh) | 2016-07-29 | 2023-06-23 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体和其使用方法 |
WO2018075798A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
IE87414B1 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
CN110709511A (zh) | 2017-08-28 | 2020-01-17 | 加利福尼亚大学董事会 | 腺相关病毒衣壳变体及其使用方法 |
BR112020010790A2 (pt) | 2017-12-01 | 2020-11-10 | Glaxosmithkline Biologicals S.A. | purificação da saponina |
WO2020030572A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
JP2022535091A (ja) | 2019-06-05 | 2022-08-04 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
WO2024017827A1 (en) | 2022-07-19 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Continuous process for vaccine production |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4258029A (en) | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
DE3521994A1 (de) | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
US5292869A (en) * | 1989-04-27 | 1994-03-08 | The Board Of Governors Of The University | Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same |
CA2032914A1 (en) | 1989-12-26 | 1991-06-27 | Peter C.K. Lau | Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides |
US5443832A (en) | 1990-04-16 | 1995-08-22 | Institut Swisse De Recherches Experimentales Sur Le Cancer | Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
US5552146A (en) * | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
US5993826A (en) | 1993-03-02 | 1999-11-30 | Board Of Regents, The University Of Texas | Methods and compositions relating to useful antigens of moraxella catarrhalis |
US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
US5607846A (en) * | 1994-05-17 | 1997-03-04 | Research Foundation Of State University Of New York | Vaccine for moraxella catarrhalis |
US6764682B1 (en) * | 1994-06-16 | 2004-07-20 | Aventis Pasteur Limited | Adjuvant compositions containing more than one adjuvant |
AU4133496A (en) * | 1994-10-25 | 1996-05-15 | Kansas State University Research Foundation | Method of culturing m. bovis in low available iron media and production of infectious bovine keratoconjunctivitis vaccine therefrom |
US6335018B1 (en) * | 1995-05-01 | 2002-01-01 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US6440425B1 (en) * | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US7341727B1 (en) * | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
CA2274495C (en) * | 1996-12-20 | 2009-06-02 | Board Of Regents, The University Of Texas System | Uspa1 and uspa2 antigens of moraxella catarrhalis |
US6541616B1 (en) * | 1998-10-01 | 2003-04-01 | Antex Biologics Inc. | Moraxella catarrhalis protein, gene sequence and uses thereof |
US6391313B1 (en) * | 1999-07-15 | 2002-05-21 | Aventis Pasteur Limited | Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis |
NZ517235A (en) * | 1999-07-27 | 2004-01-30 | Aventis Pasteur | Recombinant high molecular weight major outer membrane protein of moraxella |
MY137246A (en) | 2002-04-30 | 2009-01-30 | Jfe Steel Corp | Method and instrument for measuring bead cutting shape of electric welded tube |
-
1996
- 1996-03-26 US US08/621,944 patent/US6440425B1/en not_active Expired - Fee Related
- 1996-04-29 EP EP96910872A patent/EP0826052A1/en not_active Withdrawn
- 1996-04-29 AU AU53941/96A patent/AU722132B2/en not_active Ceased
- 1996-04-29 BR BR9608241-0A patent/BR9608241A/pt not_active Application Discontinuation
- 1996-04-29 US US08/945,567 patent/US6448386B2/en not_active Expired - Fee Related
- 1996-04-29 CA CA002219889A patent/CA2219889A1/en not_active Abandoned
- 1996-04-29 JP JP53287696A patent/JP3771265B2/ja not_active Expired - Fee Related
- 1996-04-29 WO PCT/CA1996/000264 patent/WO1996034960A1/en active Application Filing
-
1997
- 1997-11-03 MX MX9708438A patent/MX9708438A/es unknown
-
1999
- 1999-02-05 HK HK99100499A patent/HK1015412A1/xx not_active IP Right Cessation
-
2002
- 2002-06-20 US US10/175,282 patent/US20030170657A1/en not_active Abandoned
- 2002-06-20 US US10/175,275 patent/US20030171254A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU722132B2 (en) | 2000-07-20 |
AU5394196A (en) | 1996-11-21 |
EP0826052A1 (en) | 1998-03-04 |
US20030171254A1 (en) | 2003-09-11 |
MX9708438A (es) | 1998-06-28 |
CA2219889A1 (en) | 1996-11-07 |
US20010014672A1 (en) | 2001-08-16 |
US6440425B1 (en) | 2002-08-27 |
JP3771265B2 (ja) | 2006-04-26 |
US20020068070A1 (en) | 2002-06-06 |
WO1996034960A1 (en) | 1996-11-07 |
HK1015412A1 (en) | 1999-10-15 |
US6448386B2 (en) | 2002-09-10 |
US20030170657A1 (en) | 2003-09-11 |
JPH11502415A (ja) | 1999-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9608241A (pt) | Proteìna de membrana externa maior de moraxella com alto peso molecular | |
BR0012974A (pt) | Composição de vacina | |
BR9610872A (pt) | Proteìna receptora de transferrina de moraxella | |
BR9712518A (pt) | Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico | |
ATE181572T1 (de) | Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe | |
ATE252640T1 (de) | Verbindungen zur immunotherapie und diagnose von tuberkulose | |
BR9809445A (pt) | Polipeptìdeo compreendendo uma porção imunogênica de um antìgeno de m. tubercolosis, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processos para indução de imunidade protetora em um paciente, processo de detecção de tuberculose em um paciente,e , kit de diagnóstico. | |
BR0315228A (pt) | vacinas de polipeptìdeo para ampla proteção contra linhagens meningocócicas hipervirulentas | |
BR0111830A (pt) | Método de produção de partìculas semelhantes ao vìrus da influenza (vlps), vlps da influenza, vlps quiméricas, proteìnas da influenza, composições imunogênica e farmacêutica, métodos de imunizar contra a infecção causada pelo vìrus da influenza ou por um microorganismo patogênico outro que não o vìrus da influenza, método de tratamento, e, célula hospedeira transfectada, infectada ou transformada com uma molécula de dna recombinante | |
BR9610511B1 (pt) | construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica. | |
BR9712556A (pt) | Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno | |
HUP9702377A2 (hu) | Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek | |
DE69322166T2 (de) | Prüfung auf ein vielfache resistenz gegen antibiotika verursachendes operon | |
BR9713854A (pt) | Macromolécula e processo de preparar a mesma | |
Miyoshi-Akiyama et al. | Purification and partial characterization of a product from Yersinia pseudotuberculosis with the ability to activate human T cells | |
DE69736276D1 (de) | Menschliche dnase resistent gegen actininhibitoren | |
PT787144E (pt) | Proteina principal cd da membrana externa de moraxella | |
BR9407144A (pt) | Processo para a expressão de alto nível da proteina de membrana externa P2 de haemophilus influenzae tipo B (HIB-P2) em E.coli; processo de purifição da proteina de membrana externa P2 ou proteina de fusão da mesma;processo de reduplicação da proteina de membrana externa P2 ou proteina de fusão obtida; proteina de membrana externa P2 reduplicada, substancialmente pura, a partir de haemophilus influenzae tipo B (HIB-P2) ou proteina de fusão da mesma; vacina compreendendo a proteina de membrana externa P2 de hamophilus influenzae tipo B (HIB-P2) ou uma proteina de fusão da mesma; processo para obter uma proteina P2 ou conjugado proteina de fusão P2-polissacarídeo; processo para evitar a meningite bacteriana em um animal; vetor pNV-3; vetor pNV-2, e vetor pNV-6 | |
BR9713540A (pt) | Procedimento para a expressão do gene do vìrus da dengue | |
SE9500418L (sv) | Nya försvagade Pseudomonas aerugionos stammar | |
BR9708005A (pt) | C3 convertase resistente à regulação para baixo | |
BR9608482A (pt) | Genes receptores de transferrina | |
DE69835522D1 (de) | Das 74 kilodalton protein der äusseren membran von moraxella catarrhalis | |
BR9908234A (pt) | Proteìna de membrana externa leptospiral, lipl32 | |
BR9909576A (pt) | Genes de receptor de transferrina de moraxella |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
HKFN | Application deemed withdrawn (deleted) | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |